The drugs industry is an enormous multibillion businesses encompassing an immense number of companies involved in the design, production and marketing of drugs worldwide. According to the type of drugs the market can be dived into the following segments: diabetes, antifungal, antidepressant, antithrombotic, hepatitis drugs, analgesics and a far more.
Currently, the drugs market is undergoing a recovery phase in the wake of the recent decline provoked by the economic slump. The market growth is spurred by increasing demand for drugs across the globe, rising incidence of chronic as well as infectious diseases, population ageing, product innovations and constant technological advancements. North America and Europe are the most prominent regional markets. Bristol-Myers Squibb, Pharmacia, GlaxoSmithKline, Merck & Co, Novartis, Eli Lilly, Pfizer, Johnson & Johnson, Allergan, Schering-Plough, Bayer and Abbott Labs are amid global drugs arena giants.
A huge collection of the research reports covering the drugs market at different geographies can be found under this MarketPublishers’ catalogue. The researches provide comprehensive assessment of the market, characterize major market trends and disclose essential market indicators. The reports describe the competitive scenario and indicate top market players. In addition, future prospects for the drugs market are thoroughly studied in the research reports.
Publications found:
8,499
Sort by:
Osteomyelitis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Osteomyelitis Pipeline Overview The Q4 Osteomyelitis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
52 pages
Peanut Allergy R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Peanut Allergy Pipeline Overview The Q4 Peanut Allergy pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
134 pages
Pemphigus Vulgaris R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Pemphigus Vulgaris Pipeline Overview The Q4 Pemphigus Vulgaris pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under devel...
October 2020
72 pages
Phenylketonuria (PKU) R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Phenylketonuria (PKU) Pipeline Overview The Q4 Phenylketonuria (PKU) pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of dru...
October 2020
81 pages
Plague R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Plague Pipeline Overview The Q4 Plague pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Plague, p...
October 2020
52 pages
Polio (Poliomyelitis) R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Polio (Poliomyelitis) Pipeline Overview The Q4 Polio (Poliomyelitis) pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
101 pages
Pompe Disease R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Pompe Disease Pipeline Overview The Q4 Pompe Disease pipeline report is part of the VPA Metabolic Disorder disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
101 pages
Pyelonephritis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Pyelonephritis Pipeline Overview The Q4 Pyelonephritis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
81 pages
Rabies R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Rabies Pipeline Overview The Q4 Rabies pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Rabies, p...
October 2020
97 pages
Rhinovirus Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Rhinovirus Infections Pipeline Overview The Q4 Rhinovirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs u...
October 2020
71 pages
Rotavirus Infections R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Rotavirus Infections Pipeline Overview The Q4 Rotavirus Infections pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs und...
October 2020
58 pages
Schistosomiasis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Schistosomiasis Pipeline Overview The Q4 Schistosomiasis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under develop...
October 2020
48 pages
Sjogren Syndrome R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Sjogren Syndrome Pipeline Overview The Q4 Sjogren Syndrome pipeline report is part of the VPA immunology disease pipeline service. This quarterly review describes the pipeline of drugs under developme...
October 2020
147 pages
Smallpox R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Smallpox Pipeline Overview The Q4 Smallpox pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Small...
October 2020
64 pages
Tetanus R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Tetanus Pipeline Overview The Q4 Tetanus pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Tetanus...
October 2020
132 pages
Toxoplasmosis R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Toxoplasmosis Pipeline Overview The Q4 Toxoplasmosis pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
30 pages
Tularaemia R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Tularaemia Pipeline Overview The Q4 Tularaemia pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for T...
October 2020
45 pages
Typhoid Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Typhoid Fever Pipeline Overview The Q4 Typhoid Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development...
October 2020
61 pages
Warts R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Warts Pipeline Overview The Q4 Warts pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development for Warts, prov...
October 2020
108 pages
Yellow Fever R&D Pipeline Analysis Report, Q4 2020
US$ 1,699.00
Yellow Fever Pipeline Overview The Q4 Yellow Fever pipeline report is part of the VPA 110 Infectious Disease pipeline service. This quarterly review describes the pipeline of drugs under development f...
October 2020
63 pages
Gummy Vitamins Market by Product Type (Multivitamins, Single Vitamins), Source (Animal, Plant), Packaging Type (Bottles & Jars, Pouches), Distribution Channel (Store-Based, Online), End User (Adult, Children), and Region - Global Forecast to 2025
US$ 4,950.00
According to MarketsandMarkets, the global gummy vitamins market size is estimated to be valued at USD 5.9 billion in 2020 and projected to reach USD 10.6 billion by 2025, recording a CAGR of 12.5%, i...
October 2020
194 pages
Global Anticancer Drugs Market Size study, By Drug Type - Cytotoxic Drugs (Alkylating Agents, and Antimetabolites), Targeted Drugs (Monoclonal Antibodies and Tyrosine Kinase Inhibitors), and Hormonal Drugs), By Therapy Type (Chemotherapy, Targeted Therapy, and Immunotherapy), By Cancer Type (Lung Cancer, Breast Cancer, Leukemia, and Colorectal Cancer), and Regional Forecasts 2020-2027
US$ 2,568.00
Global Anticancer Drugs Market is valued approximately at USD 105.4 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 6.7% over the forecast period 2020-2027. Sales of...
October 2020
200 pages
Analgesics in Middle East and Africa
US$ 1,325.00
Analgesics in the Middle East and Africa faces challenges against the backdrop economic slowdown. Self-medication, generics and product innovation have positively influenced demand, but lower consumer...
October 2020
46 pages
Pain Management Drugs Market by Drug Class, (NSAIDS, Anesthetics, Anticonvulsant, Anti-Migraine Drugs, Antidepressant Drugs, Opioids, Non-Narcotics, and Analgesics), Indication (Arthritic Pain, Neuropathic Pain, Cancer Pain, Chronic Pain, Post-Operative Pain, Migraine, Fibromyalgia, Bone Fracture, Muscle Sprain/Strain, Acute Appendicitis, and Other Indications), Pain Type (Chronic and Acute) : Global Opportunity Analysis and Industry Forecast, 2019–2027
US$ 6,168.00
... of the market. However, drug exploitation, patent expiration of prescription pain medication drugs, and availability of substitutes such as pain relief devices restrain the market growth. The global pain management drugs market ...
September 2020
266 pages
Vitamin D: Global Market Intelligence (2018-2028)
US$ 4,250.00
REPORT OBJECTIVES The report “Vitamin D Market: Global Market Intelligence (2018-2028) provides market intelligence on the different market segments, based on Market Dynamics, Distribution Channel, P...
September 2020
90 pages
Global Drug Screening Laboratory Services Market Size study, by Service Type (Workplace Drug Testing, Clinical Toxicology), by Sample Type (Urine Sample, Oral Fluid Sample, Hair Sample, Others), by End-User (Hospital Laboratories, Clinical Laboratories, Others) and Regional Forecasts 2020-2027
US$ 3,218.00
Global Drug Screening Laboratory Services Market is valued approximately at USD 6.7 billion in 2019 and is anticipated to grow with a healthy growth rate of more than 9.4% over the forecast period 202...
September 2020
200 pages
Acne Drugs: Global Markets
US$ 2,750.00
Report : This report offers a detailed picture of the acne drugs market. It highlights the current and future market potential for acne drugs and provides a detailed analysis of the competitive enviro...
September 2020
110 pages
